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Objective: A case series on different vascular malformations (VM) treated with percuta-
neous occlusion in children and adults is presented. Background: Percutaneous
occlusion is usually the preferred treatment method for VM. Previous series have
mostly focused on single types of devices and/or VM. Methods: Retrospective analysis
of all patients who underwent percutaneous occlusion of VM in a single center, from 1995
to 2014, excluding patent ductus arteriosus. Clinical and angiographic data, procedural
details, implanted devices, and complications were assessed. Procedural success was
defined as effective device deployment with none or minimal residual flow. Predictors of
procedural failure and complications were determined by multivariate analysis. Results: A
total of 123 VM were intervened in 47 patients with median age of 12 years (25 days–76
years). The VM included 55 pulmonary arteriovenous fistulae, 39 aortopulmonary collat-
erals, 10 systemic venovenous collaterals, 8 peripheral arteriovenous fistulae, 5
Blalock-Taussig shunts, 4 coronary fistulae, and 2 Fontan fenestrations. The 143 de-
vices used included 80 vascular plugs, 38 coils, 22 duct occluders, and 3 foramen
ovale or atrial septal defect occluders. Median vessel size was 4.5 (2.0–16.0) mm and
device/vessel size ratio was 1.4 (1.1–2.0). Successful occlusion was achieved in 118
(95.9%) VM, including three reinterventions. Four (3.3%) clinically relevant complica-
tions occurred, without permanent sequelae. Lower body weight was independently
associated with procedural failure and complications. Conclusion: To our knowledge,
this is the largest series on different VM occluded percutaneously in children and
adults, excluding patent ductus arteriosus. Percutaneous occlusion was effective and
safe, using different devices. VC 2015 Wiley Periodicals, Inc.
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INTRODUCTION
Vascular malformations (VM) are a diverse group of
cardiovascular disorders [1,2]. Percutaneous occlusion
of anomalous blood vessels was first reported almost
50 years ago in a patient with patent ductus arteriosus
[3]. In parallel with the ongoing developments in tech-
nology, different devices are now available in the cath-
eterization laboratory armamentarium, including
different vascular plugs, coils, duct occluders, among
others [4,5]. In addition, increasing expertise has
allowed improvements in the technique of VM occlu-
sion [6]. Therefore, a variety of arterial and venous
VM are currently closed percutaneously in many cen-
ters and this is usually the preferred treatment method
if technically feasible [7–9].
Patent ductus arteriosus is by far the most common
VM, with extensive literature reporting results of its
percutaneous closure [6,7]. The largest series on percu-
taneous occlusion of other VM in pediatric and adult
patients are mostly focused on a single type of device
or a single VM [5,8–14]. In our opinion, this may rep-
resent a shortcoming because different devices may be
adequate according to specific vessel characteristics
and in clinical practice a large variety of VM require
treatment [4,7,8]. Several factors may influence the
effectiveness and safety of percutaneous occlusion of
VM and the predictors of adverse outcome have not
been completely addressed in previous studies [7,8].
We report, to the best of our knowledge, the largest
series on effectiveness and safety of percutaneous clo-
sure of different arterial and venous VM in pediatric
and adult patients, excluding patent ductus arteriosus.
The predictors of procedural failure and complications
were analyzed.
METHODS
Patients and Data Collection
The institutional ethics committee approved the
study protocol. All cases of pediatric and adult patients
that underwent percutaneous occlusion of VM in our
center in the last 20 years, from January 1995 to De-
cember 2014, were retrospectively analyzed. The cases
of percutaneous closure of patent ductus arteriosus
were excluded considering the robust data already pub-
lished on effectiveness and safety of its percutaneous
occlusion [6,7]. Demographic, clinical, and angio-
graphic data, procedural details, implanted devices, and
complications were collected from a systematic registry
carried out since 1995, and were confirmed using the
clinical records. The VM features and the angiographic
result following intervention were characterized by
reviewing the original angiograms.
Definitions
The VM were classified as arterial or venous accord-
ing to the afferent segment. The diameter of the VM
was measured at the planned site for device deployment
and was approximated to the closest 0.5 mm. The de-
vice size to vessel size ratio was calculated for all VM.
Procedural success was defined as effective device
deployment with none or minimal residual flow,
assessed by angiography during the procedure.
The assessed complications included death, stroke,
myocardial ischemia, arrhythmia, device malposition or
embolization, vascular complications (occlusion, tear
or dissection, and pseudoaneurism or arteriovenous fis-
tula formation), hemolysis secondary to incomplete
VM occlusion, any bleeding requiring transfusion and
renal failure, occurring during hospital stay or after dis-
charge [15,16]. Complication severity was graded from
1 to 5 according to the CHARM score [17]. Adverse
events were considered clinically relevant if they were
at least moderate (grade 3), including those potentially
life-threatening if not treated by medication or by pro-
cedural intervention, or those needing monitoring in
the intensive care unit [17].
Statistical Analysis
Discrete data are presented as frequency (percentage),
whereas continuous variables are presented as median
(minimum-maximum). Procedural success and complica-
tion rates were calculated by indexing to the number of
intervened VM. Predictors of procedural failure were
determined by univariate analysis (considering all clini-
cal and angiographic data, procedural details, and
implanted devices) using the chi-square and Mann–
Whitney tests, when appropriate, and by multivariate
logistic regression analysis. When the Pearson correla-
tion coefficient between two continuous variables was
>0.60, only the variable judged to be clinically more
important was entered in the multivariate model in order
to avoid multicollinearity. Predictors of complications
(of any grade of severity) were determined using the
same methodology. The level of significance considered
was a¼ 0.05. Data were analyzed using the software
Statistical Package for the Social Science for Windows,
version 20.0 (SPSS Inc, Chicago IL).
RESULTS
A total of 123 VM were intervened in 47 patients,
of which 32 (68.1%) were under 18 years. Clinical
data is presented in Table I. A total of 72 procedures
were performed, including reinterventions, as specified
below. Four experienced interventionists (two pediatric
cardiologists and two adult cardiologists) were
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responsible for all procedures throughout the analyzed
period. In pediatric cases the procedure was performed
by a pediatric cardiologist; in adult cases it was per-
formed by an adult cardiologist in collaboration with a
pediatric cardiologist. All followed the same catheteri-
zation and occlusion protocol, with no preferences
regarding technique or tools.
An antiplatelet agent was started 24 hr before the pro-
cedure. Catheterization was performed under general an-
esthesia in pediatric patients (50 procedures, 69.4%) and
on conscious sedation in adult patients. After obtaining
the vascular access, antibiotic prophylaxis and a bolus
of 100 IU/kg of unfractionated heparin were adminis-
tered, and full anticoagulation was maintained through-
out the procedure (2.5 activated clotting time). The
VM was assessed by selective angiography; in 56.9% of
cases a balloon test occlusion was performed. The inter-
vened VM are detailed in Table II.
During the studied period there was a remarkable de-
velopment of new and more suitable devices for vascular
occlusion (Table III). From 1995 to 1998, coils (Flipper
detachable embolization coil, Cook Inc., IN) were the
only devices available for percutaneous embolization in
our center (Fig. 1). Since the introduction of the Amplat-
zer Duct Occluder (AGA Medical Corp., MN) in 1998,
this device was preferred over coils in VM sized over
4 mm (avoiding the use of multiple coils), particularly if
the VM had high flow velocity, despite its off-label use
(Fig. 2). In 2003, plugs became available in our center
and have been the preferred devices. Since then, in our
institutional protocol, VM with a diameter up to 14 mm
were preferentially closed with a device of the Amplat-
zer Vascular Plug (AVP) family (AGA Medical Corp.,
MN) (Fig. 3, Supporting Information Videos 1 and 2)
and the use of coils was limited to small VM (usually up
to 4 mm). During the studied period, VM over 14 mm of
diameter were closed with Amplatzer Septal Occluder or
Amplatzer PFO Occluder devices (AGA Medical Corp.,
MN), introduced in 1998 and 2000, respectively. The
143 implanted devices, which were selected according
to the VM size and flow, included 80 of the AVP family,
38 Flipper detachable embolization coils, 22 of the
Amplatzer Duct Occluder family, and 3 Amplatzer PFO
Occluders or Amplatzer Septal Occluder (Table III).
Angiography was performed in all cases immediately
after device deployment and in some it was repeated 10
min after the deployment. Angiographic and procedural
details are presented in Table IV. Success was achieved
in 115 (93.5%) VM. In the remaining 8 (6.5%), the de-
vice was not successfully deployed or it did not effec-
tively occlude the VM. The cases of procedural failure
included three aortopulmonary collaterals, two pulmo-
nary arteriovenous fistulae, one Blalock-Taussig shunt,
one coronary fistula, and one systemic venovenous col-
lateral. Of these, two aortopulmonary collaterals and the
Blalock-Taussig shunt were successfully intervened in a
second procedure, accounting for the three (2.4%) rein-
terventions. Successful occlusion was therefore achieved
in 118 (95.9%) VM, including the reinterventions.
In the absence of complications, patients were dis-
charged on the day following the procedure and anti-
platelet therapy was maintained for six months. Seven
(5.7%) procedural complications occurred. Two cases
of contained vascular tears of aortopulmonary collater-
als occurred without clinical impact and without the
need for medical or procedural intervention. One case
of transient atrioventricular block with spontaneous re-
versal, possibly mediated by vagal activity, occurred
during a pulmonary arteriovenous fistula occlusion.
Two cases of inferior limb ischemia followed the cath-
eterization procedures using femoral artery access and
TABLE I. Clinical Characteristics
N¼ 47
Age (years)a 12 (25 days–76 years)
Female, N (%) 24 (51.1)
Weight (kg)a 45.0 (1.9–90.0)
Congenital structural heart disease, N (%) 28 (59.6)
Glenn surgery or Fontan circulation, N (%) 16 (34.0)
Number of procedures per patient 1.5
Number of intervened vessels per patient 2.6
aMedian values with range.
TABLE II. Intervened Vascular Malformations
Vascular malformation N (%) Sizea Devices Success N (%)
Arterial 111 (90.2)
Pulmonary arteriovenous fistula 55 (44.7) 5.5 (3.5–16.0) 36 AVP, 15 coils, 12 ADO, 1 ASO 53 (96.4)
Aortopulmonary collateral 39 (31.7) 4.0 (2.0–9.0) 28 AVP, 18 coils, 2 ADO 36 (92.3)
Peripheral arteriovenous fistula 8 (6.5) 4.5 (3.0–9.0) 8 AVP, 1 ADO 8 (100.0)
Blalock-Taussig shunt 5 (4.1) 5.0 (4.0–6.0) 5 coils, 3 ADO 4 (80.0)
Coronary fistula 4 (3.3) 7.0 (5.0–9.0) 3 AVP 3 (75.0)
Venous 12 (9.8)
Systemic venovenous collateral 10 (8.1) 4.5 (3.0–12.0) 5 AVP, 4 ADO 9 (90.0)
Fontan fenestration 2 (1.6) 15.0 (14.0–16.0) 2 APFO 2 (100.0)
ADO: Amplatzer Duct Occluder family; APFO: Amplatzer PFO Occluder; ASO: Amplatzer Septal Occluder; AVP: Amplatzer Vascular Plug family.
aMedian values with range.
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were reversed with intravenous anticoagulation. One
case of macroscopic hematuria occurred after device
deployment with incomplete closure of a Blalock-
Taussig shunt, disappearing after successful occlusion
in a second procedure. One coil embolized to the fem-
oral artery and was removed surgically, uneventfully.
Therefore, three (2.4%) complications were minor
(grade 2) and four (3.3%) were moderate or severe
(grades 3 or 4), none resulting in permanent sequelae.
In univariate analysis, procedural failure was associ-
ated with lower body weight (median 15.0, 3.8–
52.0 kg vs. 58.0, 1.9–90.0 kg, P¼ 0.006), younger age
(median 4 years, 2 months-15 years vs. 15 years, 25
days–76 years, P¼ 0.006), smaller vessel size (median
3.0, 2.0–5.0 mm, vs. 5.0, 2.0–16.0 mm, P¼ 0.031),
and coil use (16.7% failure in VM treated with coils
vs. 4.0% in VM treated without coils, P¼ 0.046).
Since body weight and age were significantly corre-
lated (r¼ 0.65, P< 0.001), only body weight was
included in the multivariate model. Lower body weight
was independently associated with procedural failure
(OR 1.05, 95% CI 1.01, 1.10, P¼ 0.019).
Regarding the seven complications, lower body
weight (median 10.0, 3.8–26.5 kg vs. 55.0, 1.9–
90.0 kg, P¼ 0.003), younger age (median 17 months, 2
months–11 years vs. 16 years, 25 days–76 years,
P¼ 0.001), and coil use (16.7% complications in VM
treated with coils vs. 3.0% in VM treated without coils,
P¼ 0.027) were associated with the occurrence of
complications in univariate analysis. Considering the
correlation between body weight and age, only body
weight was included in the multivariate model, for the
reasons aforementioned. Lower body weight was inde-
pendently associated with the occurrence of complica-
tions (OR 1.08, 95% CI 1.01, 1.15, P¼ 0.018).
DISCUSSION
We report a single center experience on percutane-
ous occlusion of different arterial and venous VM,
using a variety of devices. This treatment option was
effective and safe in patients with a wide range of
ages, from 25 days to 74 years.
Fig. 1. A: Aortopulmonary collateral with 2 mm of diameter before intervention, (B) and after clo-
sure with a Flipper detachable embolization coil (arrow), with no residual flow through the device.
TABLE III. Devices Used During the Study Period
N 1995–1999 2000–2004 2005–2009 2010–2014 Available in our center
Vascular plugs
Amplatzer Vascular Plug 68 – 1 45 22 2003
Amplatzer Vascular Plug II 8 – – 1 7 2007
Amplatzer Vascular Plug 4 4 – – – 4 2009
Duct occluders
Amplatzer Duct Occluder 20 2 15 3 – 1998
Amplatzer Duct Occluder II 2 – – – 2 2008
Amplatzer PFO Occluder 2 – – – 2 2000
Amplatzer Septal Occluder 1 1 – – – 1998
Flipper detachable embolization coil 38 23 5 2 8 1995
Number of devices 143 26 21 51 45
Number of intervened vascular malformations 123 18 17 46 42
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Percutaneous occlusion is usually the preferred treat-
ment method for VM if technically feasible [8,9]. Pat-
ent ductus arteriosus is relatively common and it is
probably the VM that most often requires percutaneous
closure in pediatric patients [6,7]. Since there is al-
ready extensive data on percutaneous occlusion of pat-
ent ductus arteriosus [6,7], on the contrary to other
VM, it was excluded from our study.
The five largest published series on pediatric and
adult patients with different arterial and venous VM
treated with percutaneous occlusion, excluding patent
ductus arteriosus, are discussed below [5,8–11]. Four
of these have focused on a specific type of device,
even though different devices may be adequate
Fig. 2. A: Blalock-Taussig shunt with 5 mm of diameter and high flow velocity before inter-
vention (arrow), (B) an Amplatzer Duct Occluder device well positioned, (C) and minimal
residual flow after deployment.
Fig. 3. A: Large pulmonary arteriovenous fistula with 13 mm of diameter before intervention
(arrow), (B) and after closure with an Amplatzer Vascular Plug II (arrow), with no residual flow
through the device.
TABLE IV. Angiographic and Procedural Details
Vessel size (mm)a 4.5 (2.0–16.0)
Device size (mm)a 6.0 (3.0–18.0)
Device size/vessel size ratioa 1.4 (1.1–2.0)
Number of devices per vesselb 1 [0–5], 1.2 0.6
Fluoroscopy time (minutes)a 17 (7–44)
Procedural success, N (%) 115 (93.5)
Complete occlusion, N (%) 98 (79.7)
Minimal residual flow, N (%) 17 (13.8)
Procedural failure, N (%) 8 (6.5)
Device not deployed, N (%) 5 (4.1)
Incomplete occlusion by the device, N (%) 3 (2.4)
Final success (including reinterventions), N (%) 118 (95.9)
aMedian values with range.
bMedian value with range, mean SD.
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according to specific vessel characteristics, including
diameter and flow [4,5,8–10]. Perry et al. [10] have
reported the use of Gianturco coils to embolize 77
VM, including aortopulmonary collaterals, Blalock-
Taussig shunts, arteries involved in pulmonary seques-
trations, and vena cava. The success rate was 94.7%
and 10.4% of complications occurred, including device
embolization and severe hemolysis after incomplete
occlusion of a Blalock-Taussig shunt [10]. More
recently, three series have focused on the AVP family
[5,8,9]. In a multicentric study, Hill et al. [8] reported
the occlusion of 84 vessels in 52 patients with congeni-
tal heart disease using 89 AVP devices. Vessels
included collaterals, pulmonary arteriovenous fistulae,
coronary artery fistulae, transhepatic tracts, central
shunts, patent ductus arteriosus, and excluded hepatic
vein [8]. Complete vessel occlusion was demonstrated
within 10 min in 94% of devices and one case required
surgical intervention due to significant residual flow in
a patent ductus arteriosus [8]. In a single center regis-
try by Schwartz et al. [9], 52 vessels of different types
were occluded in 50 patients using the AVP and AVP
II devices. Two (3.8%) access site complications
occurred; in a median follow-up of one week there was
imaging or clinical evidence of complete occlusion of
all VM, including those with residual flow immediately
after device deployment [9]. Therefore, minimal resid-
ual flow after deployment may be an adequate measure
for procedural success, as we considered in our analy-
sis. In another study by Barwad et al. [5], complete
occlusion occurred in 92% of the 39 intervened VM,
using the AVP, AVP II, AVP III, and AVP 4 devices,
with no complications. Girona et al. [11] have reported
the use of coils and vascular plugs to occlude 51 dif-
ferent VM, all showing complete occlusion, without
complications. The reintervention rate in our cohort is
non-negligible. Nevertheless, the final success rate is in
line with the aforementioned series, most of which are
relatively recent, even though the definitions for tech-
nical success are not homogeneous in the literature
[5,8–11]. The rate of complications in our series
appears to be higher than the reported in these studies,
but definitions of adverse events were not homogene-
ous as well [5,8–11]. Of note, the rate of adverse
events that we report is comparable with that described
in large multicentric registries of different catheteriza-
tion procedures [5,8–16].
If patent ductus arteriosus is not considered, other
series on percutaneous occlusion of different VM in
pediatric and adult patients include smaller samples
and the results are therefore difficult to compare
[18–25]. Larger series have only analyzed the occlu-
sion of pulmonary arteriovenous fistulae, predomi-
nantly in adults [12–14]. The procedural and clinical
results were good but the devices used were almost re-
stricted to coils or detachable balloons [12–14]. Data
on percutaneous occlusion of different VM is presented
in our study, using different devices, which may be
more useful for clinicians than data focused on a single
VM or a specific device [8,9].
Predictors of procedural failure have not been com-
pletely addressed in previous studies [8,9]. Septal and
duct occluder devices have been reported to be difficult
to deliver due to their bulkier profiles, especially across
tortuous and angulated vessels, on the contrary to vascu-
lar plugs, which may be easier to track and to deliver
[5,8]. Coils have been associated with lower success
rate of VM occlusion [5,10,26]. In our series, 6.5% of
the VM were not successfully occluded in the first pro-
cedure, either due to inadequate catheter support which
precluded device deployment, or due to incomplete
occlusion by the device. Coil use was associated with
procedural failure in univariate analysis, along with
lower body weight, younger age, and smaller vessel
size. Lower body weigh was independently associated
with procedural failure, which may reflect a more diffi-
cult percutaneous access to the VM and a poorer sup-
port for device delivery. Regarding safety, the use of
coils was associated with higher rate of complications in
univariate analysis; this finding is consistent with previ-
ous series, which also reported safety issues with the
use of coils, including embolization [5,10,26]. Lower
body weight was the only independent predictor of com-
plications, which may be related to a higher risk of
access site complications, poorer support for device
delivery, and more fragile and prone to rupture VM.
Further prospective studies are needed to evaluate the
consistency of these findings.
Limitations
The retrospective nature of the study is the main li-
mitation. However, the results are based on a fairly
complete systematic registry carried out since 1995, on
clinical, angiographic, and procedural data. This study
truly reflects clinical practice over a long period of 20
years, including clinical and technical challenges.
CONCLUSION
To the best of our knowledge, this is the largest se-
ries on different arterial and venous VM treated with
percutaneous occlusion in pediatric and adult patients,
excluding patent ductus arteriosus. This treatment
option was effective and safe, although lower body
weight was associated with procedural failure and com-
plications.
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